The US Food and Drug Administration (FDA) has approved a new drug to treat adult and child cancer patients based on genetic mutations rather than on types of disease.
A drug called Vitrakvi and its scientific name LAROTECTINIB has been approved for the treatment of cancer that appears anywhere in the body.
NITCAVI is the first drug designed from the start to fight the genetic mutations of the disease, regardless of the type of cancer, NBC said.
FDA approval is an important step in the treatment of cancer, "FDA Commissioner Scott Gottlieb said in a statement." Basic tumor genes, regardless of where they come from the body. "
"This will help patients get" timely treatment, "he said.
He said the drug treats people with different tumors but has a common genetic mutation, noting that this was not available a decade ago because knowledge of genetic mutations at that time was less than now.